ANNEX PUBLISHERS

Journal of Obesity and Overweight

ISSN: 2455-7633

Open Access
Case Report
Max Screen >>

Self-Experiencing “The Healthiest Weight”

Received Date: April 28, 2016 Accepted Date: May 15, 2017 Published Date: May 17, 2017

Copyright: © 2017 Peregrin-Alvarez JM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Related article at Pubmed, Google Scholar

Abstract

The Ideal Weight has been an interesting topic for years. The Healthiest Weight should be accurate and unique for everyone. Current methods use the BMI (Body Mass Index) as an indicator of a person’s optimal weight. However, BMI has some issues, leading to inefficient weight management programs. Successful programs should consider the optimal timing for the brain control of weight-presetting, the fundamental of the Lipostat theory, not yet reported in humans. In this study, the bases for successful Weight Management Programs are proposed by BMI sub-categorization, current state-of-the-art mobile technology and self-experimentation. This is the first reported long-term human self-experiment involving successful weight loss, metabolic adaptation and weight-presetting, consistent with the Lipostat theory. New concepts and ideas are raised, setting up the bases for further experimental investigations.

Keywords: BMI; Ideal Weight; Healthiest Weight; Weight Management; Lipostat theory; Weight loss

List of Abbreviations: BMI: Body Mass Index; HA: Healthiest Area; M: Milestone

Introduction

The best body weight has been a topic of debate for a long time. The healthiest weight should be accurate and unique for everyone. Current methods use the BMI [1] as a widely used indicator of a person’s optimal weight, measuring body fat based on height and weight. However, due to the variety of body types, muscle distribution, bone mass, etc, BMI is not appropriate as the only indication for diagnosis. One of the BMI disadvantages is misclassification [2]. BMI only cannot tell either the possibility of someone with Normal BMI to return to (or becoming) unhealthy in the future, which can be one of the reasons why ~80% of people succeeding in short-term weight loss are not able to maintain it long term [3]. Furthermore, caution should be observed when using the BMI as a measure for interpreting overweight and obesity as body composition can be highly variable yet have the same BMI. To avoid such situations, successful weight management programs should consider the required timing for feedback signals originating in adipose tissue to influence the brain centers that control eating behaviour and activity (metabolic and motor), the fundamental of the Lipostat theory [4], yet to be studied in humans. This theory controls long-term appetite, therefore responsible for the control of body weight. As fat deposits accumulate, satiety signals are sent to the hypothalamus in response in an attempt to suppress the feeling of hunger and maintain a constant body weight. Despite the mentioned caveats, the BMI remains as a widely used screening tool for determining obesity risk due to excess fat in several target populations as it is simple, inexpensive and easy to use. In this study, BMI values are sub-categorized and further validated “the healthiest area” (HA), a more stringent and efficient BMI category. Hypotheses are: 1) HA is suitable for long term weight loss and successfully achieving a healthy weight since it will set the body weight away from both overweight and underweight risks; and 2) since it would take a considerable longer amount of time for an unhealthy person to reach HA, this will facilitate weight-presetting, consistent with the Lipostat theory. These hypotheses were subjected to self-experimental validation (experimentation in which the experimenter conducts the experiment on her- or himself), aiming to set up the bases for implementation of effective weight management programs.

Materials and Methods

A single Spanish individual was subjected to case study. While there is a lack of studies comparing Spanish to other communities, studies in the United States showed that ethnic minorities, such us Hispanic, are overrepresented among the overweight and obese population, which highlight the importance of culture in the development of “culturally competent” weight-loss interventions [5].

The values of BMI Normal category (18.5–25) were transformed into ideal weights, based on height and weight, and further sub-categorized into three coloured categories (overweight risk, pink area; healthiest area (HA), blue area; and underweight risk, green area).

HA calculation

For example, an adult with height 5’10” (1.78meters) HA=144lbs (65.3kg) - 159lbs (72.2kg)

HA Formula

HA min = min + (max-min)/3
HA max = max - (max-min)/3

Three time milestones (M1-M3) were implemented: M1, Normal BMI; M2, HA; and M3, HA maintenance. In M1, to create an effective negative energy balance [6], a combination of weight loss and minimum activity programs were applied, consisting of a gradual decrease of calorie intake (in this case, until a minimum of 2000kcal/day) and a minimum calorie burning (200kcal/day) [7]. In M2, calorie intake compensation was applied, allowing extra calories until a maximum of half of the total calorie burnt by activity (e.g: if 300kcal/day were burnt, a minimum 2150kcal/day intake was allowed), thus maintaining a more relaxing negative energy balance. In M3, total calorie intake compensation was applied, thus establishing an ideal energy balance (e.g: 400kcal/day out, 2400kcal/day in).

If individuals fully endorse weight loss-related behavioural goals and feel more competent and autonomous (self- determination theory), their efforts are more likely to result in long-lasting behaviour change [8]. Both calorie in (meals) / out (work outs) were self-monitored by easy to use mobile apps [9] and subjected to calibration in case of metabolic adaptation [10]. The trickiest parts were the changing of daily habits and building long-term motivation. Simple habit-formation and rewarding strategies were implemented during M1. For example, any choice of food and activity was allowed (more encouraging than any pre-determined diet or activity implementation) [11] with the only restriction that daily meal choices should follow basic nutrition guidelines (10-35% Protein; 20-35% Fat; 45-65% Carbohydrates) [12]; for meals (calorie in), any healthy choice (e.g: veggies vs chips) was recorded as “ZERO” calorie in; for work out (calorie out), any choice of vigorous activity (e.g: running vs walking) was recorded as 2X calories out. Normal calorie values (in/out) provided by the mobile apps were recorded during M2 and M3.

For the purpose of this article, to facilitate the calculation of HA values and the reproducibility of the results an online draft-app was created (https://app.appsgeyser.com/MyHealthyWeight). By introducing height and weight, BMI, Ideal Weight, and HA values are automatically displayed. Precomputed values can also be downloaded here (https://www.dropbox.com/s/70ze5wgy61fggse/safeline.pdf?dl=0).

Results and Discussion

Starting at weight 101kg (Figure 1a) (and height 178 cm) (31.9 BMI category obese), the Normal BMI category (25 BMI; 79kg) was reached after 5 months and 2 weeks (weight loss rate 1kg/week), and HA (22.8 BMI; 72kg) after another 5 months and a half (weight loss rate 0.32kg/week) (11 months after initiating the experiment; average weight loss rate 0.66kg/week). The healthiest weight (21.7 BMI; 69kg) was achieved after another 4 months, and by choice, the lowest HA value (20.6 BMI; 65kg) 14months after. The milestones implementation provided with a robust and efficient way of gradually driving a person’s weight to the desired values while costing less than conventional treatments [13]. Successful autonomy and habit formation was achieved by psychological reinforcement [14] likely due to the selection of the right experimental set up and the strong encouragement provided by the positive results. HA has so far been successfully reached and maintained for more than 2 years and a half since the beginning of the self-experiment. Total weight loss ~36kg. Weight loss rate always complied with International Weight Loss guidelines [15] throughout the three milestones. High peaks along the weight loss line correspond to high seasons with positive energy balance, and small up/down peaks correspond to metabolic adaptations. When metabolic adaptation was observed (Figure 1b), an increased food intake and physical activity was applied for compensation. Interestingly, the normal weight trend was always shortly recovered by reimplementing either a normal or compensated energy balance, and weight within HA was maintained for years. This suggests a successful healthy weight-presetting, consistent with the Lipostat theory. A low HA-presetting was chosen by personal preference, suggesting that a personal control of body weight is possible after a successful weight-presetting, further supporting this theory.

Conclusion

The combination of technology and personal science [16] works in harmony. HA was successfully achieved and maintained. HA categorization has advantages, compared to the only use of BMI: HA warns about situations such as overweight/underweight risks, it avoids misclassification (e.g., cases close to Normal BMI), and it works in conjunction with BMI, establishing max/min limits. Experiment tracking was crucial. However, mobile technology allowed a close interaction [17], providing autonomy [8] and strengthening motivation [18]. While studies show that ~80% of people are not able to keep weight loss long, likely due to lack of motivation over time [3], the implementation of any choice of food/activity (personal preference vs pre-established diets/routines) and simple rewarding strategies are probably the keys for building up positive-thinking and long-term motivation [19], as well as successful habit-formation [20], achieved 8-10weeks after implementation. This study represents the first successful long-term human self-experiment involving weight loss, metabolic adaptation and weight-presetting, consistent with the Lipostat theory. This study set up the bases for the systematic implementation of efficient weight management programs. With sufficient funding these results can be adapted and reproduced on a larger scale. Future studies should be able to further validate these results and answering some interesting questions raised here such as the exact timing the Lipostat requires for healthiest weight-presetting.

Acknowledgement

I thank Dra.I Peregrin-Alvarez for reviewing this manuscript, helpful comments, and unconditional support throughout these years. And my friend JM Medina-Gutierrez, M.Sc.Eng. for his ideas building the online tool and psychological support.

1 Wu F, Zhao S, Yu B, Chen YM, Wang W et al. (2020) “A new coronavirus associated with human respiratory disease in China,” Nature 579: 265-69.
2 Huang C, Wang Y, Li X, Ren L, Zhao J et al. (2020) “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” Lancet 395: 497-506.
3 Xie C, Zhao H, Li K, Zhang Z, Lu X et al. (2020) “The evidence of indirect transmission of SARS-CoV-2 reported in Guangzhou, China,” BMC Public Health 20: 1-9.
4 Weiss SR and Navas-Martin S (2005) “Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus,” Microbiol. Mol. Biol. Rev 69: 635-64.
5Huang Y, Yang C, Xu XF, Xu W, Liu SW (2020) “Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for Covid-19,” Acta Pharmacol. Sin 41: 1141-9
6 Wan Y, Shang J, Graham R, Baric RS, Li F (2020) “Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus,” J. Virol 94: 7.
7Tanonaka K, Marunouchi T (2020) “Angiotensin-converting enzyme 2,” Folia Pharmacol. Jpn 147: 120-1.
8 Keidar S, Kaplan M, Gamliel-Lazarovich A (2007) “ACE2 of the heart: From angiotensin I to angiotensin (1-7),” Cardiovasc. Res 73: 463-9.
9 Hubert C, Houot AM, Corvol P, Soubrier F (1991) “Structure of the angiotensin I-converting enzyme gene: Two alternate promoters correspond to evolutionary steps of a duplicated gene,” J. Biol. Chem 266: 15377-83.
10 Castellon R, Hamdi H (2007) “Demystifying the ACE Polymorphism: From Genetics to Biology,” Curr. Pharm. Des 13: 1191-8.
11Lin C, Yang HY, Wu CC, Lee HS, Lin YF et al. (2014) “Angiotensin-converting enzyme insertion/deletion polymorphism contributes high risk for chronic kidney disease in Asian male with hypertension-a meta-regression analysis of 98 observational studies,” PLoS One 9: 1-16.
12 Mohammadi F, Shahabi P, Zabani S, Ziaii AA (2008) “Insertion/deletion gene polymorphism and serum level of angiotensin converting enzyme,” Tanaffos 7: 18-22.
13 Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) “A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase,” J. Biol. Chem 275: 33238-43.
14 Tikellis C, Thomas MC (2012) “Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease,” Int. J. Pept 2012.
15 Landazuri P, Granobles C, Loango N (2008) “Gender differences in serum angiotensin-converting enzyme activity and blood pressure in children: an observational study.,” Arq. Bras. Cardiol 91: 352-7
16 Beacon TH, Delcuve GP, Davie JR (2020) “Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus” 1, Genome 14: 1-14.
17Rath S, Perikala V, Jena AB, Dandapat J (2021) “Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs.” Biomed Pharmacother 143: 112095.
18 Paital B (2020) “Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context.” Sci Total Environ 729: 139088.
19Vargas-Alarcón G, Hernández-Pacheco G, Rodríguez-Pérez JM, Pérez-Hernández N, Pavón Z et al. (2003) “Angiotensin-converting enzyme gene (ACE) insertion/deletion polymorphism in Mexican populations.” Hum Biol 75: 889-96.
20 Wu YH, Li JY, Wang C, Zhang LM, Qiao H (2017) “The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke.” J Clin Lab Anal 31: e22033.
21 Lu N, Yang Y, Wang Y, Liu Y, Fu G et al. (2012) “ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects.” Mol Biol Rep 39: 6581-9.
22Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF et al. (2014) “From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension.,” Front. Physiol 5: 227.
23Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M et al. (2021) “Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein.,” Biochimie 180: 143-8.
24Pouladi N, Abdolahi S (2021) “Investigating the ACE2 polymorphisms in Covid-19 susceptibility: An in silico analysis.,” Mol. Genet. genomic Med 9: e1672.
25 Green MR, Sambrook J (2017) “Precipitation of DNA with isopropanol,” Cold Spring Harb. Protoc 2017: 673-4.
26 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P et al. (1990) “An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels,” J. Clin. Invest 86: 1343-6
27 Riera-Fortuny C, Real JT, Chaves FJ, Suarez-Varela MM, Martinez-Triguero ML et al. (2005) “The relation between obesity, abdominal fat deposit and the angiotensin-converting enzyme gene I/D polymorphism and its association with coronary heart disease,” Int. J. Obes 29: 78-84.
28 He Q, Fan C, Yu M, Wallar G, Zhang ZF et al. (2013) “Associations of ACE Gene Insertion/Deletion Polymorphism, ACE Activity, and ACE mRNA Expression with Hypertension in a Chinese Population,” PLoS One, vol. 8, no. 10, pp. 1–9, doi: 10.1371/journal.pone.0075870.
29 Philipp CS, Dilley A, Saidi P, Evatt B, Austin H et al. (1998) “Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty.,” Thromb. Haemost 80: 869-73.
30 Lee YJ and Tsai JCR (2002) “ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients,” Diabetes Care 25: 1002-100.
31Reyes MV (2002) “The disproportional impact of Covid-19 on African Americans,” Health Hum. Rights 22: 299-307.
32 Pati A, Mahto H, Padhi S, Panda AK (2020) “ACE deletion allele is associated with susceptibility to SARS-CoV-2 infection and mortality rate: An epidemiological study in the Asian population,” Clin. Chim. Acta 510: 455-8.
33 Gómez J, Albaiceta GM, García-Clemente M, López-Larrea C, Amado-Rodríguez L et al. (2020) “Angiotensin-converting enzymes (ACE, ACE2) gene variants and Covid-19 outcome.,” Gene 762: 145102.
34 Hatami N, Ahi S, Sadeghinikoo A, Foroughian M, Javdani F et al. (2020) “Worldwide ACE (I/D) polymorphism may affect Covid-19 recovery rate: an ecological meta-regression,” Endocrine, vol. 68, no. 3, pp. 479–484, doi: 10.1007/s12020-020-02381-7.
35 Delanghe JR, Speeckaert MM, De Buyzere ML (2020) “The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in Covid-19 infections.,” Clinica chimica acta; international journal of clinical chemistry 505: 192-3.
36Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT et al. (2020) “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,” Cell 181: 281-92.e6.
37 Morshed M, Khan H, Akhteruzzaman S (2002) “Association between angiotensin I-converting enzyme gene polymorphism and hypertension in selected individuals of the Bangladeshi population.,” J. Biochem. Mol. Biol 35: 251-4.
38Oliveira AC, Richards EM, Raizada MK (2020) “Pulmonary hypertension: Pathophysiology beyond the lung,” Pharmacol. Res 151: 104518.
39 Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM (2008) “Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease,” Kidney Int., vol. 74, no. 12: 1610-6.
40 D’Onofrio N, Scisciola L, Sardu C. Trotta MC, De Feo M et al. (2021) “Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte,” Cardiovasc. Diabetol 20: 99.
41 Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S et al. (2021) “Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2,” Commun. Biol 4: 475.
42 Dyer O (2020) “Covid-19: Black people and other minorities are hardest hit in US,” BMJ 369: m1483.
43Aung AK, Aitken T, Teh BM, Yu C, Ofori-Asenso R et al. (2020) “Angiotensin converting enzyme genotypes and mortality from Covid-19: An ecological study,” J. Infect 81.
44 Verma S, Abbas M, Verma S, Khan FH, Raza ST et al. (2021) “Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of Covid-19 patients,” Infect. Genet. Evol 91: 1-5.
45 Mir MM, Mir R, Alghamdi MAA, Alsayed BA, Wani JI et al. (2021) “Strong association of angiotensin converting enzyme-2 gene insertion/deletion polymorphism with susceptibility to sars-cov-2, hypertension, coronary artery disease and Covid-19 disease mortality,” J. Pers. Med 11: 1-21.
46 Möhlendick B, Kristina S, Katharina B, Carina E, Nina B et al. (2021) “ACE2 polymorphism and susceptibility for SARS-CoV- -2 infection and severity of Covid-19.,” Pharmacogenet. Genomics 31: 165-71.
47 Srivastava A, Bandopadhyay A, Das D (2020) “Genetic Association of ACE2 rs2285666 Polymorphism With Covid-19 Spatial Distribution in India,” 11: 7-12.
48 Strafella C, Caputo V, Termine A, Barati S, Gamberdella S et al. (2020) “Analysis of ace2 genetic variability among populations highlights a possible link with Covid-19-related neurological complications,” Genes (Basel) 11: 1-10.
49 Pabalan N, Tharabenjasin P, Suntornsaratoon P, Jarjanazi H, Muanprasat C (2021) “Ethnic and Age-Specific Acute Lung Injury/Acute Respiratory Distress Syndrome Risk Associated With Angiotensin- Converting Enzyme Insertion/Deletion Polymorphisms, Implications for COVID-19: A Meta-Analysis”, Infect Genet Evol: J Mol Epidemiol Evol Genet Infect Dis 88: 104682.
50 Sidhwani SK, Mieza T, Khatun A, Shaikh F, Khan R et al. (2023) “Angiotensin-converting enzyme 2 (ACE2) polymorphisms and susceptibility of severe SARS-CoV-2 in a subset of pakistani population,” Virol J 20: 120.
51 Çelik SK, Genç GÇ, Pişkin N, Açikgöz B, Altinsoy B et al. (2021) “Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of Covid-19: A case study,” J. Med. Virol 93: 5947-52.
52 Novelli A, Biancolella M, Borgiani P, Cocciadiferro D, Colona VL et al. (2020) “Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients,” Hum. Genomics 14: 10-5.
53 Asselta R, Paraboschi EM, Mantovani A, and Duga S (2020) “ACE2 and TMPRSS2 Variants and Expression as Candidates to Sex and Country Differences in Covid-19 Severity in Italy,” SSRN Electron. J 12: 10087-98.

Journal Of Obesity and Overweight

Figures at a glance
Figure 1
Figure 1: Representative agarose gel image of ACE and ACE2 gene PCR-RFLP. ACE Insertion-Deletion genotypes after PCR-AFLP (A) and restriction digestion product bands of ACE2 after performing PCR-RFLP (B)

Feature

Variable

Control

Case

OR (95% CI)

p

Age

>40
≤40

15
35

40
60

ref (1)
0.64 (0.31-1.32)

 

0.232

Gender

Female
Male

20
30

40
60

ref (1)
1.00 (0.50-2.00)

 

1.000

Comorbidities

Renal disease
Cardiovascular disease
Asthma
Diabetes
Hypertension

4
5

8
5
6

10
31

39
56
47

ref (1)
2.48 (0.55-11.06)

1.95 (0.48-7.40)
4.48 (1.02-19.62)
3.13 (0.74-13.19)

 

0.234

0.345
0.046
0.119

Smoking habit

No
Yes

31
19

37
63

ref (1)
2.78 (1.38-5.60)

 

0.004

Table 1: Baseline characteristics of controls and cases

Gene

Genotype

Control

Case

OR (95% CI)

p

 

rs4646994

II

16

18

ref (1)

 

ID

28

56

1.78 (0.79-4.00)

0.165

DD

6

26

3.85 (1.26-11.74)

0.017

 

rs2285666

GG

31

21

ref (1)

 

GA

13

31

3.52 (1.50-4.25)

0.004

AA

6

48

11.81 (4.29-32.54)

<0.0001

Table 2: Association of ACE rs4646994 and ACE2 rs2285666 polymorphism with Covid-19 infection

rs2285666

rs4646994

No

Yes

OR (95% CI)

p

GG
(N=21)

II
ID
DD

13
13
16

8
8
5

ref (1)
1.00 (0.29-3.47)
0.51 (0.13-1.93)

 

1.000
0.320

GA
(N=31)

II
ID
DD

25
17
20

6
14
11

ref (1)
3.43 (1.10-10.70)
2.29 (0.72-7.28)

 

0.034
0.160

AA
(N=48)

II
ID
DD

44
14
38

4
34
10

ref (1)
26.71 (8.06-88.51)
2.89 (0.84-9.98)

 

<0.0001
0.092

Table 3: Correlation between rs4646994 and rs2285666 polymorphism in Covid-19 infection

Comorbidity

No

Yes

OR (95% CI)

p

Renal disease

32

2

ref (1)

 

Cardiovascular disease

28

6

3.43 (0.64-18.37)

0.150

Asthma

26

8

4.92 (0.96-25.22)

0.055

Diabetes

19

15

12.63 (2.60-61.38)

0.002

Hypertension

24

10

6.67 (1.33-33.28)

0.021

Table 4: Association of ID+AA with comorbid conditions in cases

Partnered Content Networks

  • Cancer Science
  • Vaccine Studies
  • Gynecology
  • Food Nutrition
  • Nursing Science
  • Public Health
  • The Pharma
  • Infectious Disease
  • Neuro Care
  • Catalysis
  • Neonatal Biology
  • Neonatal Disorders
  • Mutation
  • Nanotechnology
  • Toxicology
  • Dark Biotechnology
  • Pollution Toxicology
  • Cell Biology
  • Bioanalytical Research
  • Renal Disorders
  • The Astrophysics
  • Sleep Physiology
  • Epidemiology
  • Histology